🇺🇸 FDA

Intelligence · Drug directory

Withdrawn Drug Applications

Drugs with withdrawn or discontinued regulatory applications in the US or EU — useful for competitive and label-history research.

Quick answer

Withdrawn applications: NovaPharmaNews tracks 229 pharmaceutical drugs in this segment. Drugs with withdrawn or discontinued regulatory applications in the US or EU — useful for competitive and label-history research.

229 drugs · Withdrawn · by data quality · Page 3 of 10

  1. boceprevir

    VICTRELIS

    ORAL FDA: approved · EMA: withdrawn

    J05AE

  2. cidofovir

    VISTIDE

    INTRAVENOUS FDA: approved · EMA: withdrawn

    J05AB12

  3. collagenase clostridium histolyticum

    XIAPEX

    INJECTION FDA: approved · EMA: withdrawn

    M09AB02

  4. crisaborole

    STAQUIS

    TOPICAL FDA: approved · EMA: withdrawn

    D11AH06

  5. daclizumab

    ZENAPAX

    INJECTION FDA: approved · EMA: withdrawn

    L04AC01

  6. daprodustat

    JESDUVROQ

    ORAL FDA: approved · EMA: application withdrawn

    B03XA

  7. desvenlafaxine

    APO-DESVENLAFAXINE MR Pfizer Australia Pty Ltd

    ORAL FDA: approved · EMA: application withdrawn · TGA: approved

  8. doripenem

    DORIBAX

    INTRAVENOUS FDA: approved · EMA: withdrawn

    J01DH04

  9. duvelisib

    COPIKTRA

    ORAL FDA: approved · EMA: withdrawn

    L01EM04

  10. edaravone

    RADICAVA Lacuna Pharma Pty Ltd

    ORAL FDA: approved · EMA: application withdrawn · TGA: approved · PMDA: approved

    N07

  11. eluxadoline

    TRUBERZI

    ORAL FDA: approved · EMA: withdrawn

    A07

  12. ensifentrine

    OHTUVAYRE

    INHALATION FDA: approved · EMA: application withdrawn

    R03BX

  13. gadofosveset trisodium

    ABLAVAR (PREVIOUSLY VASOVIST)

    INTRAVENOUS FDA: approved · EMA: withdrawn

    V08CA

  14. gadoversetamide

    OPTIMARK

    INJECTION FDA: approved · EMA: withdrawn

    V08CA06

  15. ganciclovir

    VITRASERT IMPLANT

    OPHTHALMIC FDA: approved · EMA: withdrawn

    J05AB06

  16. ingenol mebutate

    PICATO

    TOPICAL FDA: approved · EMA: withdrawn

    D06BX02

  17. lifitegrast

    XIIDRA

    OPHTHALMIC FDA: approved · EMA: application withdrawn

    S01XA25

  18. lixisenatide

    LYXUMIA

    SUBCUTANEOUS FDA: approved · EMA: withdrawn · PMDA: approved

    A10BJ03

  19. necitumumab

    PORTRAZZA

    INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL FDA: approved · EMA: withdrawn

    L01

  20. obiltoxaximab

    NYXTHRACIS (PREVIOUSLY OBILTOXAXIMAB SFL)

    INJECTION FDA: approved · EMA: withdrawn

    J06BB22

  21. ocriplasmin

    JETREA

    INTRAVITREAL FDA: approved · EMA: withdrawn

    S01XA22

  22. ombitasvir

    VIEKIRAX

    ORAL FDA: approved · EMA: withdrawn

    J05AP53

  23. oteseconazole

    VIVJOA

    ORAL FDA: approved · EMA: application withdrawn

    J02

  24. palifermin

    KEPIVANCE

    INJECTION FDA: approved · EMA: withdrawn

    V03AF08

Frequently asked questions

How many withdrawn drugs are listed?

229 drug profiles match this regulatory segment in our published index.

Where does approval data come from?

Profiles combine FDA Drugs@FDA, EMA EPAR references, and regional authority feeds. See our data sources page for attribution.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.